Advances on pentraxin 3 in osteoporosis and fracture healing.
10.12200/j.issn.1003-0034.2023.04.018
- Author:
Jia-Jun LU
1
;
Yan SUN
1
;
Xuan ZHANG
1
;
Qiao-Qi WANG
2
;
Zhou-Yi XIANG
3
;
Yi-Qing LING
2
;
Pei-Jian TONG
2
;
Tao-Tao XU
2
Author Information
1. The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China.
2. The First Affiliated Hospital of Zhejiang Chinese Medical Unversity, Hangzhou 310006, Zhejiang, China.
3. Qingbo Street Community Health Service Center, Shangcheng District, Hangzhou, Hangzhou 310002, Zhejiang, China.
- Publication Type:Journal Article
- Keywords:
Fracture;
Osteoblast;
Osteoclast;
Osteoporosis;
Pentraxin 3
- MeSH:
Animals;
Male;
Mice;
Bone Resorption/metabolism*;
Cell Differentiation;
Fracture Healing/genetics*;
Osteoblasts;
Osteoclasts;
Osteogenesis;
Osteoporosis/genetics*;
Phosphatidylinositol 3-Kinases/pharmacology*
- From:
China Journal of Orthopaedics and Traumatology
2023;36(4):393-398
- CountryChina
- Language:Chinese
-
Abstract:
Pentaxin 3 (PTX3), as a multifunctional glycoprotein, plays an important role in regulating inflammatory response, promoting tissue repair, inducing ectopic calcification and maintaining bone homeostasis. The effect of PTX3 on bone mineral density (BMD) may be affected by many factors. In PTX3 knockout mice and osteoporosis (OP) patients, the deletion of PTX3 will lead to decrease of BMD. In Korean community "Dong-gu study", it was found that plasma PTX3 was negatively correlated with BMD of femoral neck in male elderly patients. In terms of bone related cells, PTX3 plays an important role in maintaining the phenotype and function of osteoblasts (OB) in OP state;for osteoclast (OC), PTX3 in inflammatory state could stimulate nuclear factor κ receptor activator of nuclear factor-κB ligand (RANKL) production and its combination with TNF-stimulated gene 6(TSG-6) could improve activity of osteoclasts and promote bone resorption;for mesenchymal stem cells (MSCs), PTX3 could promote osteogenic differentiation of MSCs through PI3K/Akt signaling pathway. In recent years, the role of PTX3 as a new bone metabolism regulator in OP and fracture healing has been gradually concerned by scholars. In OP patients, PTX3 regulates bone mass mainly by promoting bone regeneration. In the process of fracture healing, PTX3 promotes fracture healing by coordinating bone regeneration and bone resorption to maintain bone homeostasis. In view of the above biological characteristics, PTX3 is expected to become a new target for the diagnosis and treatment of OP and other age-related bone diseases and fracture healing.
